Actively Recruiting
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours
Led by IHU Strasbourg · Updated on 2026-04-16
60
Participants Needed
2
Research Sites
4 weeks
Total Duration
On this page
Sponsors
I
IHU Strasbourg
Lead Sponsor
L
Luxembourg Institute of Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
Pancreatic ductal adenocarcinoma (PDAC) is a digestive cancer with the poorest outlook due to late diagnosis and limited treatment response. This research focuses on creating and validating patient-derived organoids from biopsy samples to enable personalized tumor analysis. The study aims to confirm that these organoids reflect the original tumor's morphology, genetic features, and tumor marker expression, advancing personalized cancer care. The study involves patients undergoing an echo-endoscopic fine-needle biopsy (EUS-FNB) to collect pancreatic tumor samples. One to two biopsies will be used for regular diagnostic analysis, while an additional biopsy will be used to create organoids. This biopsy is split into three parts: one for organoid culture, one preserved for genetic comparison, and one analyzed using innovative imaging technology (Dynamic Full-field Optical Coherence Tomography). Blood samples will also be collected for genomic analysis. Participants will undergo standard EUS-FNB biopsy with an extra sample taken for research purposes. Researchers will evaluate organoid development over 8 weeks and assess their accuracy in replicating tumor features. Additional evaluations include protocol effectiveness over 3 months and imaging analysis on the first day. The study ensures careful monitoring of tumor characteristics and genetic profiles to support personalized treatment strategies.
CONDITIONS
Brief Title
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient over 18 years of age.
- Undergoing echo-endoscopy with certainty or suspicion of fine needle biopsy (EUS-FNB).
- Suspicion of pancreatic lesion.
- Able to receive, understand information about the research protocol, and give consent.
- Affiliated with the French social security system.
You will not qualify if you...
- Not scheduled for endoscopy with certainty or suspicion of fine needle biopsy (EUS-FNB).
- Undergoing echo-endoscopy but at high risk that may prevent EUS-FNB.
- Has degenerated Intraductal papillary mucinous neoplasm (IPMN).
- Had acute pancreatitis within 4 weeks before EUS.
- Pregnant or breastfeeding.
- Under court protection.
- Under guardianship or curatorship.
- In a situation of social vulnerability.
- Under legal protection or unable to express opposition.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day 1
Participants undergo an echo-endoscopy with fine needle biopsy (EUS-FNB) to obtain tissue samples and blood withdrawal for genomic and organoid analysis.
1 visit (in-person)
Duration - Up to 3 months
Participants' biopsied tumour samples are cultured to develop organoids. These organoids are analyzed for morphological, genetic, and proliferative characteristics over time.
No additional visits; analyses are conducted on collected samples
Trial Site Locations
Total: 2 locations
1
Centre d'Endoscopie Digestive
Strasbourg, France
Actively Recruiting
2
Department of hepato-gastroenterology
Strasbourg, France
Actively Recruiting
Research Team
A
Armelle TAKEDA
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here